REG - Oxford BioDynamics - CIRRP Award Update

Oxford BiodynamicsAnnouncement

07/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241007:nRSG0901Ha&default-theme=true

RNS Number : 0901H  Oxford BioDynamics PLC  07 October 2024

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

CIRRP Award Update

Oxford, UK - 7 October 2024 - Oxford BioDynamics, Plc (AIM: OBD, the
Company), a precision clinical diagnostics company bringing specific and
sensitive tests to the practice of medicine based on its EpiSwitch® 3D
genomics platform, notes that the UK Cancer Immunotherapy Response Research
Platform (CIRRP) funding for biomarker development for cancer immunotherapies
has been awarded by the government-run Office for Life Sciences and the
Medical Research Council to the MANIFEST consortium led by the Francis Crick
Institute.

OBD was part of the EpiSwitch consortium, led by the University of Oxford, and
including the University of Birmingham and five NHS Trusts, which was
shortlisted for the award.

In its feedback to the EpiSwitch consortium, the Panel explained its decision:
"The Panel agreed that the application was based on an interesting technology
that was already routinely used in the USA and in private UK clinics. However,
Members agreed that while this was an excellent collaboration between a
diagnostics company and a single  sic  academic group, it didn't fulfil the
expectations of the Opportunity to build a legacy UK-wide consortium to
deliver research into cancer immunotherapy.

Members agreed that the application concentrated on moving the current
technology into standard practice within the NHS and would have been
strengthened by providing greater detail on new tests to be developed with a
focus on mechanistic molecular insight as well as correlating the blood work
back to tumour data."

Alexandre Akoulitchev, CSO of Oxford BioDynamics, said:

"We wish the MANIFEST consortium every success in their research program on
biomarkers for response to immunotherapies. The award decision will support
the national flagship - Francis Crick Institute and the infrastructure of many
other key research and NHS institutions around the country. The proposed
extensive systematic approach will document many interesting aspects of
molecular events around biopsy of tumors and sequencing information, within
research space, with further expansion to blood and stool readouts. This will
oversee early biomarker discovery and would start the process of pre-clinical
model building.

"Last month, at the 14(th) Clinical Biomarkers and Companion Diagnostics World
Summit in Boston, OBD presented in a key-note talk the latest real-world
evidence from adoption of our commercialy available Checkpoint Inihibitor
Response (CiRT) test in the US, including in the PROWES national observational
registry study. The Company also shared results of the development and
validation of its Hyperprogression Immune Response Test (HiRT) made possible
through the support of the Company's second PACT Award and the latest
technical developments that allows multi-choice early detection and prevention
of immune-related adverse events (irAEs), associated with common side effects
of immune checkpoint inhibitors.

"With regard to the main focus of the CIRRP program, having already
successfully completed the stages of biomarker discovery and translation to
clinical practice in immuno-oncology, our main objective remains to support
the rapid utilization of the accurate and robust CiRT test, in the UK and US."

-Ends-

For more information:

 Oxford BioDynamics Plc                  +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital                           +44 (0)20 7408 4090

(Nominated Adviser and Broker to OBD)

 Stephane Auton

 Lucy Bowden

 WG Partners                             +44 (0)20 3705 9330

 (Joint Broker to OBD)

 David Wilson / Claes Spång /

Satheesh Nadarajah / Erland Sternby

 Vigo Consulting                         +44 (0)20 7390 0230
 (Media / Analyst enquiries for OBD)

Rozi Morris                            OBD@vigoconsulting.com

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
(EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
(Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDBBDGRSGDGSL